Actinium Pharmaceuticals, Inc. (ATNM)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Actinium Pharmaceuticals, Inc. reported revenue of $90.0K. The company ran a net loss, with a net margin of -37652.2%. It held $51.77M in total assets against $43.94M in total liabilities.
Key ratios (FY2025)
-40274.4%
Operating margin
-37652.2%
Net margin
-432.6%
Return on equity
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $90.0K | — | $81.0K | $1.03M | $1.14M | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | $900.0K | — | — | — | — | — |
| Operating Income | -$36.25M | -$42.12M | -$51.92M | -$34.10M | -$24.96M | -$22.39M | -$22.07M | -$23.83M | -$26.91M | -$26.85M |
| Net Income | -$33.89M | -$38.24M | -$48.82M | -$33.02M | -$24.77M | -$22.21M | -$21.90M | -$23.65M | -$26.60M | -$24.32M |
| EPS (Diluted) | $-1.09 | $-1.27 | $-1.83 | $-1.37 | $-1.20 | — | — | — | — | — |
| Total Assets | $51.77M | $76.90M | $81.44M | $114.19M | $80.39M | $66.40M | $11.67M | $14.89M | $18.34M | $22.53M |
| Total Liabilities | $43.94M | $44.14M | $45.07M | $47.71M | $6.84M | $5.08M | $6.03M | $6.08M | $4.67M | $4.52M |
| Shareholders' Equity | $7.83M | $32.76M | $36.38M | $66.48M | $73.55M | $61.32M | $5.64M | $8.81M | $13.67M | $18.01M |
| Cash & Equivalents | $48.00M | $72.90M | $76.68M | $108.91M | $77.83M | $63.56M | $9.25M | $13.67M | $17.40M | $20.52M |
| Operating Cash Flow | -$24.58M | -$33.07M | -$47.34M | $8.64M | -$20.87M | -$21.62M | -$21.46M | -$20.57M | -$21.55M | -$20.79M |
| Capital Expenditures | $104.0K | $11.0K | $153.0K | $366.0K | $133.0K | $253.0K | $64.0K | $96.1K | $24.7K | $60.0K |
| Shares Outstanding | 31.20M | 31.20M | 27.63M | 25.67M | 22.14M | 17.53M | 5.49M | 115.70M | 80.07M | 55.80M |